Bristol-Myers' Opdualag fails Phase 3 melanoma study
Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...
Jim Cramer on Bristol-Myers (BMY): Cobenfy’s Success vs. Patent Headwinds
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.
Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund
In this piece, we will look at the stocks Jim Cramer recently discussed.
Under Trump, drug price negotiations likely to continue
Explore how Medicare drug price negotiations under the Inflation Reduction Act could evolve with the Trump administration.
BioSpace5d
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
The Globe and Mail6d
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
But the company is counting on big things from Cobenfy, its new schizophrenia drug, is the first new treatment for the ...